Role of the Akt Pathway in Prostate Cancer
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
163-175
Author(s):
Paul L. de Souza, Pamela J. Russell and John Kearsley
Elucidation of the Molecular Mechanisms of a Salicylhydrazide Class of Compounds by Proteomic Analysis
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
189-201
Author(s):
Xuefei Cao, Carmen Plasencia, Atsuko Kanzaki, Austin Yang, Terrence R. Burke Jr. and Nouri Neamati
Nitric Oxide: Cancer Target or Anticancer Agent?
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
214-236
Author(s):
Simone Mocellin
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Journal:
Current Cancer Drug Targets
Volume:
9
Page:
237-249
Author(s):
Todd M. Morgan, Theodore D. Koreckij and Eva Corey
Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
950-956
Author(s):
Steven M. Larson
Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
957-965
Author(s):
Philip S. Murphy and Mats Bergstrom
Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
966-982
Author(s):
J. Harvey Turner
Chemokine Receptors as Targets for Cancer Therapy
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
742-757
Author(s):
Xuesong Wu, Vivian C. Lee, Eric Chevalier and Sam T. Hwang
Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
758-776
Author(s):
P. Sapra Sharma, R. Sharma and T. Tyagi
Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
777-791
Author(s):
Di Chen, Vesna Milacic, Michael Frezza and Q. Ping Dou